AZ 10992

Subscribe to Selected New Research on AZ 10992

2 relevant articles (1 outcomes, 2 trials/studies) found for this Bio-Agent

Description: has antineoplastic activity; structure in first source

Also Known As:

AZ-10992; AZ10992

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kobayashi, To-Ru: 1 article (01/2007)
2.	Kuriyama, Hiroshi: 1 article (01/2007)
3.	Kajiki, Masahiro: 1 article (01/2007)
4.	Sugahara, Shu-Ichi: 1 article (01/2007)

Related Diseases

1.	Neoplasms (Cancer) 01/22/2007 - "Pharmacokinetic studies showed that there were significant increases in the amount and the exposure time of total paclitaxel in the tumors after intravenous administration of AZ10992, which explains the enhanced efficacy of AZ10992." 01/22/2007 - "Additionally, the comparative efficacy studies of AZ10992 and paclitaxel using a panel of human tumor xenografts in nude mice showed the advantages of drug-polymer conjugation" 02/01/2008 - "AZ10992 is a novel paclitaxel-carboxymethyl (CM) dextran conjugate via a Gly-Gly-Phe-Gly linker with the molecular weight (MW) of 150 kDa. Our previous studies demonstrated that AZ10992 exerts strong antitumor activity against the human tumor xenografts that are highly refractory to paclitaxel, attributable to passive tumor targeting of released paclitaxel" Get all the results and reference details, order at left...
2.	Carcinoma (Carcinomatosis) 01/22/2007 - "The in vivo antitumor study using AZ10992 against colon26 carcinoma cells, resistant to paclitaxel, supported this concept" 01/22/2007 - "A repeated intravenous administration of AZ10992 at 30 mg/kg/day (five injections for 4-days) showed complete regression of MX-1 mammary carcinoma xenografts" 01/22/2007 - "Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992)." Get all the results and reference details, order at left...
3.	Colorectal Neoplasms (Colorectal Cancer) 01/22/2007 - "Also, HT-29 colorectal tumor xenografts, which are highly refractory to paclitaxel, showed complete regression after AZ10992 administered at 30 mg/kg/day (seven injections for 4-days)" Get all the results and reference details, order at left...
3 Diseases and 2 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Polymers
3.	Dextrans (Dextran)
4.	glycylphenylalanine
5.	K 76 carboxylic acid
6.	carboxymethyl dextran
6 Drugs and Important Bio-Agents and 2 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
1 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>